NMNicholas M. Moore.

Nicholas M. Moore.

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas M. Moore. has a total of 172 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular epidemiology and clinical differentiation between Clostridioides difficile infection and colonization across three chicago medical centers

    by Andrew M. Skinner, Do Young Kim, Adam Cheknis, Michael Lin, Mary K. Hayden, Nicholas M. Moore, Amanda Harrington, Vera Tesic, Kathleen G. Beavis, Dale N. Gerding, et al.

    In a retrospective cohort study at three Chicago academic medical centers, 22/81 (27.2%) patients with a clinically adjudicated positive C. difficile test result were colonized. Recent antibiotic usage predicted true infection (adjusted odds ratio: 4.38 for infection). Restriction endonuclease analysis(REA) group Y (29.3%) replaced BI (9.3%) as the dominant strain.


  • Open Access

    Planning for the future of the American Society for Microbiology’s Health Unit by the Council on Microbial Sciences

    by Austin J. Fox, Andrea M. Prinzi, Nancy W. Wamburu, Nicholas M. Moore, Michael M. Lieberman, Kileen Shier, Nancy L. Haigwood

    In February and March 2025, the American Society for Microbiology (ASM)’s Council on Microbial Sciences (COMS) hosted a series of virtual retreats to integrate the communities of Clinical Infections and Vaccines (CIV) and Clinical and Public Health Microbiology (CPHM) under the umbrella of the new scientific unit ASM Health. Representatives from these two communities invited experts and ASM members to reflect on the current state of the science, identify challenges hindering scientific advancements, and propose recommendations for overcoming these challenges. Sessions focused on progress in (i) vaccines, therapeutics, diagnostics, and global pathogen surveillance; (ii) improving data integration and cross-agency sharing; (iii) supporting the microbial health workforce; and (iv) gaining public support and confidence in microbiology. Four major recommendations emerged for ASM Health. First, increased support for microbiological science is crucial to ensure the advancement of vaccines, therapeutics, diagnostics, and global pathogen surveillance to mitigate infectious disease threats. Second, enhancement of data integration and sharing in real-time via information systems will facilitate a deeper understanding of disease epidemiology. Third, modern approaches to recruitment, career path, and profession awareness, and dynamic training programs are necessary to achieve microbial workforce balance. Fourth, microbiologists will benefit from outreach training and resources designed to restore public trust in an environment that questions science and evidence-based approaches. ASM is uniquely positioned to take a pivotal leadership role to develop these concepts into specific programs, as well as to enhance partnerships across the spectrum to innovate in funding, both for scientific research and public health.

  • Open Access

    Antibiotic-resistance plasmid amplified among MRSA cases in an urban jail and its connected communities

    by Stephanie N. Thiede, Hannah Steinberg, Emily Benedict, Sarah Sansom, Alla Aroutcheva, Kyle J. Gontjes, Katherine Winner, Sonya Royzenblat, Ali Pirani, Robert A. Weinstein, et al.

    Jails have been hypothesized to be hotspots for the spread of methicillin-resistant Staphylococcus aureus (MRSA). We integrate genomic and epidemiologic data to investigate USA300 MRSA transmission in Cook County Jail (Illinois, USA) and its connected communities. A genome-wide association study of 308 jail isolates from 2015–2018 revealed a plasmid encoding the ermC clindamycin/erythromycin resistance gene was associated with a 6-fold increased odds of MRSA genetic linkages among detainees. Additionally, 52% of jail-onset MRSA infections carried this plasmid compared to 14% of intake colonization isolates, supporting its role in MRSA spread in the jail. Extending our analysis to 774 isolates from a local healthcare system from 2011–2014, the ermC-carrying plasmid was also associated with MRSA transmission in the larger community and was enriched among former jail detainees and those with related isolates to recently incarcerated cases. Lastly, topical clindamycin exposure before MRSA infection was associated with ermC plasmid presence in both settings, but exposure prevalence was higher in jail versus community cases (7.5% vs. 0.9%), suggesting antibiotic use in the jail may have created a favorable environment for the spread of ermC-carrying strains. These findings highlight the impact of antibiotic use in jails on antibiotic resistance in both jails and their surrounding communities.


  • Open Access

    Severe Saprochaete capitata fungemia presenting as micafungin breakthrough hepatosplenic lesions in an immunocompromised patient: case report

    by Hannakate Lichota, Eric Bhaimia, Graeme Forrest, Nicholas M. Moore

    Background: Saprochaete capitata ( S. capitata , also known as Magnusiomyces capitatus ), a yeast-like fungus commonly isolated from soil, is an emerging infection capable of disseminated infection in immunocompromised hosts, including those with hematologic malignancy. Case Summary: A 70-year-old female admitted for induction therapy for myelodysplastic syndrome (MDS) developed persistent neutropenic fever while on antibacterial and micafungin prophylaxis. Blood cultures revealed high-grade S. capitata fungemia with imaging findings of hepatosplenic involvement in the setting of a central venous catheter and interatrial shunt. The patient was successfully treated with a combination of voriconazole, amphotericin B 3 mg/kg daily, and flucytosine. She was transitioned to voriconazole monotherapy after blood culture clearance and resolution of fever. Conclusion: S. capitata may be associated with severe, disseminated infection in patients with hematologic malignancy. While there is a lack of evidence to guide optimal treatment, the organism appears to exhibit resistance to echinocandins. Expert opinion favors voriconazole as empiric treatment with the addition of intravenous liposomal amphotericin B for severe infections.


  • Navigating Nomenclature in Patient Care: Taxonomy Considerations From the College of American Pathologists’ Microbiology Committee

    by Jennifer Dien Bard, Kaede V Sullivan, Sean X Zhang, Obianuju M Anelo, Benjamin T Bradley, Marc R Couturier, Yvette S McCarter, Nicholas M Moore, Alexander D Pyden, Daniel D Rhoads, et al.

    Taxonomy classifies organisms based on shared traits, while nomenclature assigns formal names using distinct rules for bacteria, fungi, parasites, and viruses. Advances in genomic sequencing have refined microbial classification, often prompting name changes that can inadvertently impact clinical practice, including patient diagnosis, treatment, and communication among healthcare providers. Various organizations govern taxonomy and nomenclature differently across pathogen domains, and implementation of new nomenclature in clinical settings poses challenges. The College of American Pathologists has introduced requirements for laboratories to maintain consistent nomenclature across testing platforms and to consider use of contemporary nomenclature. While scientific accuracy is important, practical considerations must guide the adoption of new names to avoid confusion and ensure high-quality patient care.


  • Top Cited Papers
    Open Access

    Pathogen genomics in healthcare: overcoming barriers to proactive surveillance

    by Alexander J. Sundermann, Rossana Rosa, Patrick N. A. Harris, Evan Snitkin, Waleed Javaid, Nicholas M. Moore, Mary K. Hayden, Krisandra Allen, Kyle Rodino, Sharon J. Peacock, et al.

    Pathogen genomic surveillance in healthcare has the potential to enhance patient safety by detecting outbreaks earlier, thereby reducing morbidity and mortality. Despite benefits, there are barriers to adoption, including cost, expertise, and lack of standardized methodologies and incentives. This commentary advocates for 1) investment from healthcare payors, public health, and regulatory bodies and 2) additional research on genomic surveillance for improving patient outcomes and reducing infections. Effective implementation will require strategic investment and cross-sector collaboration.


  • Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute

    by Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein

    Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein; Amoxicillin/clavulanate Breakpoi


  • Amoxicillin-Clavulanate Breakpoints AgainstEnterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute

    by Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein

    Amoxicillin-clavulanate (AMC) is among the most frequently prescribed antibiotics globally. It has broad antibacterial activity against gram-positive, gram-negative, and anaerobic bacteria, and has been utilized to treat infections caused by a broad range of pathogens. AMC breakpoints against Enterobacterales were initially set in the 1980s but since then increases in antibiotic resistance, advances in pharmacokinetic (PK)/pharmacodynamic (PD) analyses, and publication of additional clinical data prompted a reassessment by the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing. Based on this contemporary reappraisal, the CLSI retained the Enterobacterales breakpoints but revised comments regarding dosing associated with use of the AMC breakpoints in the 2022 supplement of M100. This viewpoint provides insight into the CLSI breakpoint reevaluation process and summarizes the data and rationale used to support these revisions to the AMC Enterobacterales breakpoint.


  • Development and Validation of Three Automated High-Throughput Molecular Tests to Detect Monkeypox Virus Infections

    by Mark Anderson, Austin Hodges, Ka-Cheung Luk, Ana Olivo, Kenn Forberg, Todd V Meyer, Carolyn Strobel, Mark Kim, Dan Toolsie, Nicholas M Moore, et al.

    The 2022 outbreak of the Clade IIb MPX virus and subsequent global spread lead to an urgent need for the development of high throughput, sensitive, and reproducible diagnostic tests. We developed 3 assays to detect MPX virus, two (MPXV + and MPXV) for m2000 RealTime and one (MPXV) for Alinity m platforms. Dual-targets in E9L and B6R (MPXV+) and J2L and B7R (MPXV) genes were selected to increase detection of emerging mutations. In silico prediction of MPXV + and MPXV target sequences suggest broad detection of Orthopox viruses with MPXV + and more specific MPX virus detection with MPXV assays, respectively. Each assay incorporates an internal control to confirm expected assay performance and the Alinity m MPXV assay also contains a cellular control which assesses adequacy of sample collection. m2000 RealTime MPXV + and MPXV assay sensitivity was determined to be 3.2 PFU/mL using a reference virus culture diluted into UTM. Alinity m MPXV lower limit of detection was 200 copies/mL using MPX plasmids in pooled UTM matrix. m2000 RealTime MPXV + and MPXV assays were validated with lesion swabs in UTM and 1:1 saliva:UTM mixtures without loss of sensitivity. Commercially available and remnant clinical lesion specimens in UTM were tested with RealTime MPXV+, RealTime MPXV and Alinity m MPXV assays and demonstrated high agreement to known MPX positive specimens. RealTime MPXV+, RealTime MPXV and Alinity MPXV are high throughput and sensitive assays used for the detection of MPX virus. These assays maybe useful during MPX outbreaks.


  • Open Access

    Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit

    by Arianna Miles-Jay, Evan S. Snitkin, Michael Y. Lin, Teppei Shimasaki, Michael Schoeny, Christine Fukuda, Thelma Dangana, Nicholas Moore, Sarah E. Sansom, Rachel D. Yelin, et al.

    Despite enhanced infection prevention efforts, Clostridioides difficile remains the leading cause of healthcare-associated infections in the United States. Current prevention strategies are limited by their failure to account for patients who carry C. difficile asymptomatically, who may act as hidden reservoirs transmitting infections to other patients. To improve the understanding of asymptomatic carriers’ contribution to C. difficile spread, we conducted admission and daily longitudinal culture-based screening for C. difficile in a US-based intensive care unit over nine months and performed whole-genome sequencing on all recovered isolates. Despite a high burden of carriage, with 9.3% of admissions having toxigenic C. difficile detected in at least one sample, only 1% of patients culturing negative on admission to the unit acquired C. difficile via cross-transmission. While patients who carried toxigenic C. difficile on admission posed minimal risk to others, they themselves had a 24-times greater risk for developing a healthcare-onset C. difficile infection than noncarriers. Together, these findings suggest that current infection prevention practices can be effective in preventing nosocomial cross-transmission of C. difficile, and that decreasing C. difficile infections in hospitals further will require interventions targeting the transition from asymptomatic carriage to infection.